Calcified Tissue International

, Volume 77, Issue 2, pp 79–83 | Cite as

A Histomorphometric Study of Cortical Bone of the Iliac Crest in Patients Treated with Glucocorticoids



The effects of glucocorticoids on cancellous bone remodeling and structure are well documented but there are no reported histomorphometric studies in human cortical bone in glucocorticoid-treated patients. We have performed a histomorphometric analysis of iliac crest cortical bone in 14 patients treated with glucocorticoids, 9 females and 5 males, aged 18 to 48 years (34.1 ± 7 years) (mean ± standard deviation [SD]). The underlying disease was cystic fibrosis in 8 patients; asthma 3; and nephrotic syndrome; Crohn disease and inflammatory pseudotumor of the liver in one patient each. Results were compared with an age-matched control group of 10 premenopausal women and 4 men aged 22 to 38 years (30.1 ± 4.8 years) who were not, howerver matched for underlying disease. Cortical bone indices were assessed by image analysis. Cortical width and area were similar in the two groups. However, cortical porosity, Haversian canal number, and density were higher in patients treated with glucocorticoids compared with controls (8.4 ± 8.9% vs. 5.1 ± 3.9%; P = 0.03) (45.9 ± 23.2 vs. 31.9 ± 24.4; P =0.003) (13.7 ± 9.4 vs. 6.7 ± 3.3/mm2; P = 0.00005). Haversian canal area did not differ significantly between groups. The mean wall width of the osteons, bone formation rate (μm2/μm/day) and mineral apposition rate (μm/day) were lower in treated patients compared to controls (48.8 ± 7.1 μm vs. 59.8 ± 12.9 μm; P = 0.01) (0.056 ± 0.040 vs. 0.095 ± 0.058; P = 0.05) and (0.59 ± 0.12 vs. 0.75 ± 0.11; P = 0.002). The proportion of canals with an eroded surface was lower in the treated compared with the control group, although this difference was not statistically significant. These results demonstrate that cortical porosity is increased in patients treated with long-term glucocorticoid therapy, due mainly to an increase in the number rather than size of Haversian canals. This may be because of increased bone resorption during the early stages of glucocorticoid therapy, in combination with long-term impairment of bone formation. Effects of the underlying disease on bone remodeling may also contributed to these changes and could not be excluded in the present study; since control subjects were not matched in terms of disease status.


Cortical bone Remodelling Structural indices Glucocorticoid therapy 


  1. 1.
    Cooper, C, Coupland, C, Mitchell, M 1995Rheumatoid-arthritis, corticosteroid-therapy, and hip fractureAnn Rheuma Dis544952Google Scholar
  2. 2.
    Reid, IR 1997Steroid-induced osteoporosisOsteoporo Int7213216CrossRefGoogle Scholar
  3. 3.
    Villareal, DT, Civilelli, R, Gennari, C, Avioli, LV 1991Is there an effective treatment for glucocorticoid-induced osteoporosisCalci Tissue Int49141142Google Scholar
  4. 4.
    Cushing, H 1932The basophil adenomas of pituitary body and their clinical manifestations (pituitary basophilism)Bull Johns Hopkins Hosp50137195Google Scholar
  5. 5.
    Laan, RFJM, Buijs, WCAM, Erning, LJTO, Lemmens, JAM 1993Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral contentCalcif Tissue Int5259CrossRefPubMedGoogle Scholar
  6. 6.
    Laan, R, Vanriel, P, Vandeputte, LBA, Vanerning, L, Vanthof, MA, Lemmens, JAM 1993Low-Dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid-arthritis—a randomized, controlled studyAnn Internal Med119963968Google Scholar
  7. 7.
    Lukert, BP, Raisz, LG 1990Glucocorticoid-induced osteoporosis—pathogenesis and managementAnn Internal Med112352364Google Scholar
  8. 8.
    Saag, KG, Emekey, R, Schnitzer, TJ, Brown, JP 1998Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosisN Eng J Med339292299CrossRefGoogle Scholar
  9. 9.
    Reid, DM, Hughes, RA, Laan, RFJM, Sacco-Gibson, NA 2000Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomised trialJ Bone Miner Res1510061013PubMedGoogle Scholar
  10. 10.
    Cohen, S, Levy, RM, Keller, M, Boling, E 1999Risedronate therapy prevents corticosteroid-induced bone lossArthritis Rheum4223092318CrossRefPubMedGoogle Scholar
  11. 11.
    Staa, TP, Leufkins, HGM, Cooper, C 2000The epidemiology of corticosteroid-induced osteoporosisOsteoporosis Int13777787CrossRefGoogle Scholar
  12. 12.
    Carbonare, LD, Arlot, ME, Chavassieux, PM, Roux, JP, Portero, NR, Meunier, PJ 2001Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosisJ Bone Miner Res1697103PubMedGoogle Scholar
  13. 13.
    Bressot, C, Meunier, PJ, Chapuy, E, Lejeune, C, Edouard, C, Darby, AJ 1979Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosisMetab Bone Dis Rel Res1303311CrossRefGoogle Scholar
  14. 14.
    Dempster, DW, Arlot, MA, Meunier, PJ 1983Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosisCalcif Tissue Int35410417PubMedGoogle Scholar
  15. 15.
    Dempster, DW 1989Bone histomorphometry in glucocorticoid -induced osteoporosisJ Bone Miner Res4137141PubMedGoogle Scholar
  16. 16.
    LoCascio, V, Ballanti, P, Milani, S, Bertoldo, F, LoCascio, C, Zanolin, EM, Bonucci, E 1998A histomorphometric long-term longitudnal study of trabecular bone loss in glucocorticoid-treated patients: prednisone versus DeflazacortCalcif Tissue Int62199204CrossRefPubMedGoogle Scholar
  17. 17.
    Weinstein, RS, Powers, CC, Parfitt, AM, Manolagas, SC 2002Preservation of osteocyte viability by bisphosphonates contributes to bone strength in glucocorticoid-treated mice independently of BMD: an unappreciated determinant of bone strengthJ Bone Miner Res171133Google Scholar
  18. 18.
    Weinstein, RS, Jilka, RL, Parfitt, AM, Manolagas, SC 1998Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoid—potential mechanisms of their deleterious effects on boneJ Clin Invest102274282PubMedGoogle Scholar
  19. 19.
    Compston, JE, Yamaguchi, K, Croucher, PI, Garrahan, NJ, Lindsay, PC, Shaw, RW 1995The effects of gonadotrophin-releasing hormone agonists on illiac crest cancellous bone structure in women with endometriosisBone16261267CrossRefPubMedGoogle Scholar
  20. 20.
    Vedi, S, Compston, JE, Webb, A, Tighe, JR 1983Histomorphometric analysis of dynamic parameters of trabecular bone-formation in the iliac crest of normal British subjectsMetab Bone Dis Rel Res56974CrossRefGoogle Scholar
  21. 21.
    Vedi, S, Compston, JE, Webb, A, Tighe, JR 1982Histomorphometric analysis of bone biopsies from the iliac crest of normal British subjectsMetab Bone Dis Rel Res4231236CrossRefGoogle Scholar
  22. 22.
    Jordan, GR, Loveridge, N, Bell, KL, Power, J, Rushton, N, Reeve, J 2000Spatial clustering of remodeling osteons in the femoral neck cortex: A cause of weakness in hip fracture?Bone26305313CrossRefPubMedGoogle Scholar
  23. 23.
    Parfitt, AM, Drezner, MK, Glorieux, FH, Kanis, JA, Malluche, H, Meunier, PJ, Ott, SM, Recker, RR 1987bone histomorphometry—standardization of nomenclature, symbols, and unitsJ Bone Miner Res2595610PubMedGoogle Scholar
  24. 24.
    Vedi, S, Greer, S, Skingle, SJ, Garrahah, NJ, Ninkovic, M, Alexander, GA, Compston, JE 1999Mechanism of bone loss after liver transplantation: a histomorphometric analysisJ Bone Miner Res14281287PubMedGoogle Scholar
  25. 25.
    Shane, E, Rivas, M, McMahon, DJ, Staron, RB, Silverberg, SJ, Seibel, MJ, Mancini, D, Michler, RE, Aaronson, K, Addesso, V, Lo, SH 1997Bone loss and turnover after cardiac transplantationJ Clin Endocrino Metab8214971506CrossRefGoogle Scholar
  26. 26.
    Chappard, D, Legrand, E, Basle, MF, Fromont, P, Racineux, JL, Rebel, A, Audran, M 1996Altered trabecular architecture induced by corticosteroids: a bone histomorphometric studyJ Bone Miner Res11676685PubMedGoogle Scholar
  27. 27.
    Stellon, AJ, Davies, A, Compston, JE, Williams, R 1985Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapyGastroenterology8910781085PubMedGoogle Scholar
  28. 28.
    Elkin, SL, Vedi, S, Garrahan, NJ, Hodson, ME, Compston, JE 2002Histomorphometric analysis of bone biopsies from the iliac crest in adults with cystic fibroisAm. J. Respir Crit Cure16614701474CrossRefGoogle Scholar
  29. 29.
    Croucher, PI, Vedi, S, Motley, RJ, Garrahan, NJ, Stanton, MR, Compston, JB 1993Reduced bone formation in patients with osteoporosis associated with inflammatory bowel diseaseOsteopors Int3236241CrossRefGoogle Scholar
  30. 30.
    Dif, F, Marty, C, Baudoin, C, Vernejoul, M-C, Levi, G 2004Severe osteopenia in CFTR null miceBone35595603CrossRefPubMedGoogle Scholar
  31. 31.
    Lane, N 2001An update on glucocorticoid-induced osteoporosisRheum Dis Clin North Am27235CrossRefPubMedGoogle Scholar
  32. 32.
    Vedi, S, Purdie, DW, Ballard, P, Bord, S, Cooper, AC, Compston, JE 1999Bone remodeling and structure in postmenopausal women treated with long-term, high-dose estrogen therapyOsteoporos Int105258CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  1. 1.Department of MedicineUniversity of Cambridge School of Clinical MedicineCambridge, UK
  2. 2.Chest UnitSt. Mary’s HospitalLondon, UK
  3. 3.Deaprtment of medicineAddenbrooke’s HospitalCambridge, UK

Personalised recommendations